View Older Stories

Apr 24, 2026 06:45AM Travere Therapeutics (TVTX) PT Raised to $56 at Guggenheim

Apr 14, 2026 03:07PM Travere Therapeutics (TVTX) PT Raised to $43 at Stifel

Apr 14, 2026 11:10AM Piper Sandler Upgrades Travere Therapeutics (TVTX) to Overweight

Apr 14, 2026 10:45AM Increasing unusual put option volume: TVTX ASTX BW NUAI SCO CPB BNO LUMN LWLG RVMD AEHR KMX

Apr 14, 2026 09:13AM Travere Therapeutics (TVTX) PT Raised to $49 at BofA Securities

Apr 14, 2026 08:52AM Travere Therapeutics (TVTX) PT Raised to $44 at Wedbush

Apr 14, 2026 07:08AM Travere Therapeutics (TVTX) PT Raised to $54 at Guggenheim

Apr 14, 2026 07:07AM Travere Therapeutics (TVTX) Reiterated at Overweight by Cantor Fitzgerald on FSGS Approval

Apr 14, 2026 06:47AM H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)

Mar 24, 2026 05:03AM Citi Adjusts Catalyst Call List

Feb 19, 2026 04:01PM Travere Therapeutics (TVTX) Tops Q4 EPS by 41c

Jan 16, 2026 01:20PM Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses

Jan 14, 2026 06:48AM Guggenheim Reiterates Buy rating and Best Idea on Travere Therapeutics (TVTX)

Jan 13, 2026 01:24PM FDA extends review of Travere's FILSPARI application for FSGS to 2026

Jan 13, 2026 12:42PM Travere Therapeutics (TVTX) Halted, News Pending

Jan 13, 2026 07:27AM Travere Therapeutics (TVTX) Reiterated at Hold by Stifel After FDA Asks for More Info

Jan 13, 2026 04:57AM Stifel on Travere Therapeutics (TVTX): 'FSGS Increases Risk of CRL, Though Delay/Approval Still Possible'

Jan 12, 2026 05:00PM Travere reports record Q4 FILSPARI sales of $103 million

Dec 24, 2025 11:54AM FDA;s messaging is positive for Travere Therapeutics (TVTX) - Cantor Fitzgerald

Dec 23, 2025 05:30PM Jefferies lists 5 biotech M&A candidates for 2026

Oct 31, 2025 09:04AM Travere Therapeutics (TVTX) PT Raised to $48 at Citi, New Catalyst Watch

Oct 30, 2025 04:07PM Travere Therapeutics (TVTX) Tops Q3 EPS by 88c

Sep 26, 2025 07:02AM KDIGO guidelines include FILSPARI for IgA nephropathy treatment

Sep 22, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)

Sep 11, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)

Sep 10, 2025 11:01AM H.C. Wainwright on Travere Therapeutics (TVTX): 'We see adapted REMS as competitive advantage. We view this as positive news for Travere, particularly as it competes with Novartis’ (NVO; not rated)

Sep 10, 2025 10:30AM Jefferies on Travere Therapeutics (TVTX): 'AdCom Cancellation Clear Positive In Our View Setting Stage For Likely Approval'

Sep 10, 2025 10:11AM Stifel Reiterates Hold Rating on Travere Therapeutics (TVTX)

Sep 10, 2025 09:58AM Cantor Fitzgerald Comments on Travere Therapeutics (TVTX) Amid Shares Gaining 22pct

Sep 10, 2025 07:01AM FDA cancels advisory committee for Travere's FILSPARI in rare kidney disease

Sep 4, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)

Aug 28, 2025 07:33AM Travere Therapeutics (TVTX) PT Raised to $47 at H.C. Wainwright

Aug 7, 2025 10:06AM Travere Therapeutics (TVTX) PT Lowered to $20 at Stifel

Aug 6, 2025 04:03PM Travere Therapeutics (TVTX) Tops Q2 EPS by 16c

Jun 11, 2025 06:19AM H.C. Wainwright Assumes Travere Therapeutics (TVTX) at Buy

Jun 11, 2025 04:58AM Travere Therapeutics (TVTX) PT Lowered to $32 at Citi, Adds 90d Upside Catalyst Watch

May 19, 2025 03:38PM Travere Therapeutics (TVTX) call put ratio 1 call to 2.8 puts with a focus on June 15 and 17.50 puts

May 16, 2025 09:24AM Stifel Reiterates Hold Rating on Travere Therapeutics (TVTX)

May 16, 2025 06:37AM Cantor Fitzgerald Reiterates Overweight Rating on Travere Therapeutics (TVTX)

May 16, 2025 04:20AM Citi on Travere Therapeutics (TVTX): 'we would buy the dip', Opens 30-Day Upside Catalyst Call

May 15, 2025 04:22PM Travere Therapeutics (TVTX) Announces FDA Acceptance of sNDA for FILSPARI in FSGS

May 1, 2025 04:03PM Travere Therapeutics (TVTX) Tops Q1 EPS by 36c

Apr 29, 2025 07:07AM Travere Therapeutics (TVTX) and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy

Apr 28, 2025 07:19AM Cantor Fitzgerald Reiterates Overweight Rating on Travere Therapeutics (TVTX)

Apr 23, 2025 09:40AM Cantor Fitzgerald Reiterates Overweight Rating on Travere Therapeutics (TVTX)

Apr 10, 2025 06:28AM Travere Therapeutics (TVTX) PT Raised to $47 at Canaccord Genuity

Apr 3, 2025 07:18AM Cantor Fitzgerald Reiterates Overweight Rating on Travere Therapeutics (TVTX)

Apr 2, 2025 07:04AM Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald

Mar 31, 2025 04:31PM Travere Therapeutics (TVTX) to Present New FILSPARI Data at the National Kidney Foundation Spring Clinical Meetings 2025

Mar 17, 2025 07:01AM Travere Therapeutics (TVTX) Submits sNDA to FDA for Approval of FILSPARI

View Older Stories